Oncology Drugs - Gambia

Gambia

The revenue of the Oncology Drugs market in Gambia is estimated to reach US$0.95m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 6.80%, leading to a market volume of US$1.32m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$103,900.00m in 2024.
The demand for innovative oncology drugs in Gambia is steadily increasing, as the country strives to improve access to advanced cancer treatments.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for oncology drugs in Gambia has been increasing steadily over the years.

Customer preferences: Patients in Gambia prefer to use oncology drugs that are affordable and effective. They also tend to opt for drugs that have minimal side effects. Due to the high cost of treatment, patients often rely on government subsidies and donations from non-profit organizations to access these drugs.

Trends in the market: There has been an increase in the number of cancer cases reported in Gambia, which has led to a rise in demand for oncology drugs. This trend is partly due to the aging population, lifestyle changes, and improved diagnostic methods. The government has also been investing in cancer treatment facilities and equipment, which has led to an increase in the availability of oncology drugs.

Local special circumstances: Gambia is a low-income country, and the majority of the population lives below the poverty line. This has a significant impact on the healthcare system, as many people cannot afford to pay for healthcare services, including cancer treatment. The government has been working to improve the healthcare system by investing in infrastructure and increasing the budget for healthcare.

Underlying macroeconomic factors: The economy of Gambia is heavily dependent on agriculture, which makes up a significant portion of the GDP. The country is also heavily reliant on foreign aid and remittances from Gambians living abroad. The political instability in the country has also had an impact on the economy, leading to a lack of investment in certain sectors. These factors have contributed to the challenges faced by the healthcare system, including the availability and affordability of oncology drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.